Toosendanin: upgrade of an old agent in cancer treatment

IF 4 2区医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE

Chinese Journal of Natural Medicines Pub Date : 2024-10-01 DOI:10.1016/S1875-5364(24)60693-X

Shuwei LI , Qingyi XIONG , Yiwen SHEN , Jiayi LIN , Lijun ZHANG , Ye WU , Jinmei JIN , Xin LUAN

{"title":"Toosendanin: upgrade of an old agent in cancer treatment","authors":"Shuwei LI , Qingyi XIONG , Yiwen SHEN , Jiayi LIN , Lijun ZHANG , Ye WU , Jinmei JIN , Xin LUAN","doi":"10.1016/S1875-5364(24)60693-X","DOIUrl":null,"url":null,"abstract":"<div><div>Toosendanin (TSN), a tetracyclic triterpenoid derived from <em>Melia toosendan</em> and <em>M. azedarach</em>, demonstrates broad application prospects in cancer treatment. Although previously employed as a pesticide, recent studies have revealed its potential therapeutic value in treating various types of cancer. TSN exerts an anticancer effect <em>via</em> mechanisms including proliferation inhibition, apoptosis induction, migration suppression, and angiogenesis inhibition. However, TSN’s toxicity, particularly its hepatotoxicity, significantly limits its therapeutic application. This review explored the dual nature of TSN, evaluating both its anticancer potential and toxicological risks, emphasizing the importance of balancing these aspects in therapeutic applications. Furthermore, we investigated the incorporation of TSN into novel therapeutic strategies, such as Proteolysis-targeting chimeras (PROTAC) technology and nanotechnology-based drug delivery systems (DDS), which enhance treatment efficacy while mitigating toxicity in normal tissues.</div></div>","PeriodicalId":10002,"journal":{"name":"Chinese Journal of Natural Medicines","volume":"22 10","pages":"Pages 887-899"},"PeriodicalIF":4.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Natural Medicines","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S187553642460693X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Toosendanin (TSN), a tetracyclic triterpenoid derived from Melia toosendan and M. azedarach, demonstrates broad application prospects in cancer treatment. Although previously employed as a pesticide, recent studies have revealed its potential therapeutic value in treating various types of cancer. TSN exerts an anticancer effect via mechanisms including proliferation inhibition, apoptosis induction, migration suppression, and angiogenesis inhibition. However, TSN’s toxicity, particularly its hepatotoxicity, significantly limits its therapeutic application. This review explored the dual nature of TSN, evaluating both its anticancer potential and toxicological risks, emphasizing the importance of balancing these aspects in therapeutic applications. Furthermore, we investigated the incorporation of TSN into novel therapeutic strategies, such as Proteolysis-targeting chimeras (PROTAC) technology and nanotechnology-based drug delivery systems (DDS), which enhance treatment efficacy while mitigating toxicity in normal tissues.

查看原文本刊更多论文

Toosendanin: 改良治疗癌症的老药。

Toosendanin (TSN)是从 Melia toosendan 和 M. azedarach 中提取的一种四环三萜类化合物，在癌症治疗方面具有广阔的应用前景。虽然以前曾被用作杀虫剂，但最近的研究发现了它在治疗各种癌症方面的潜在治疗价值。TSN 通过抑制增殖、诱导凋亡、抑制迁移和抑制血管生成等机制发挥抗癌作用。然而，TSN 的毒性，尤其是肝毒性，极大地限制了其治疗应用。本综述探讨了 TSN 的双重性质，评估了其抗癌潜力和毒性风险，强调了在治疗应用中平衡这些方面的重要性。此外，我们还研究了将 TSN 纳入新型治疗策略的情况，如蛋白质分解靶向嵌合体（PROTAC）技术和基于纳米技术的给药系统（DDS），它们在提高疗效的同时减轻了对正常组织的毒性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chinese Journal of Natural Medicines INTEGRATIVE & COMPLEMENTARY MEDICINE-PHARMACOLOGY & PHARMACY

CiteScore

7.50

自引率

4.30%

发文量

2235

期刊介绍： The Chinese Journal of Natural Medicines (CJNM), founded and sponsored in May 2003 by China Pharmaceutical University and the Chinese Pharmaceutical Association, is devoted to communication among pharmaceutical and medical scientists interested in the advancement of Traditional Chinese Medicines (TCM). CJNM publishes articles relating to a broad spectrum of bioactive natural products, leading compounds and medicines derived from Traditional Chinese Medicines (TCM). Topics covered by the journal are: Resources of Traditional Chinese Medicines; Interaction and complexity of prescription; Natural Products Chemistry (including structure modification, semi-and total synthesis, bio-transformation); Pharmacology of natural products and prescription (including pharmacokinetics and toxicology); Pharmaceutics and Analytical Methods of natural products.